Floatz logo

Tas-102

Locally Advanced Papillary Renal Cell Carcinoma

M.D. Anderson Cancer CenterunclassifiedPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Locally Advanced Papillary Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
VOLITINIB
AstraZeneca
Phase 3BB
Crizotinib
National Cancer Institute (NCI)
Phase 2B

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant
BB
Indicative ·
68 / 100
View asset →
Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →